Lantheus To Acquire Evergreen Theragnostics

Lantheus acquires radiopharma CDMO Evergreen for up to $1bn
The deal includes an upfront payment of $250m, with the potential for an additional $752.5m in milestone payments.
Lantheus To Buy Evergreen Theragnostics For Over $1 Billion To Bolster Its Cancer Radiopharmaceutical Portfolio
Lantheus Holdings, Inc. (NASDAQ:LNTH) agreed to acquire Evergreen Theragnostics, Inc. in an all-cash transaction involving an upfront payment of $250 million and up to an additional $752.5 million in potential milestone payments.
Lantheus to buy radiopharma CDMO Evergreen Theragnostics for $250M upfront
Lantheus Holdings is stepping up its game in the radiopharmaceutical space by acquiring Massachusetts-based Evergreen Theragnostics for $250 million upfront.
Lantheus’s Strategic Acquisition of Evergreen Theragnostics Strengthens Radiopharmaceutical Leadership and Growth Prospects
Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on LNTH stock, giving a Buy rating yesterday.Invest with Confidence:
Lantheus Holdings to Acquire Evergreen Theragnostics
Lantheus Holdings Inc., a radiopharmaceutical-focused company, has agreed to acquire Evergreen Theragnostics Inc., in an all-cash transaction consisting of an upfront payment of $250 million and up to an additional $752.5 million in potential milestone payments.
Lantheus to Acquire Evergreen Theragnostics for $250 Million
Lantheus ( ($LNTH) ) has shared an update. On January 27, 2025, Lantheus Medical Imaging, a subsidiary of Lantheus Holdings, announced an
Lantheus acquires Evergreen Theragnostics for $250M upfront payment
Lantheus (LNTH) announced a definitive agreement to acquire Evergreen Theragnostics in an all-cash transaction consisting of an upfront payment
Lantheus is on a buying spree. Its latest deal is worth up to $1B
Lantheus Holdings Inc. is adding to its portfolio yet again, acquiring a clinical-stage radiopharmaceutical company in a deal ...
Outsourcing-pharma2d
Lantheus to acquire Evergreen in $1bn deal to expand radiopharmaceutical pipeline
Lantheus is acquiring radiopharmaceutical CDMO Evergreen Theragnostics in a deal worth up to $1 billion, expanding its manufacturing capabilities and drug pipeline. The acquisition includes Octevy, a ...
FiercePharma4d
Lantheus lays out $250M+ to get its hands on radiopharma developer and CDMO Evergreen
On a quest to carve out a spot as one of the nuclear medicine greats, Massachusetts-based radiopharmaceutical specialist ...
The Pharma Letter3d
Lantheus rides radiopharma wave with $1 billion deal
Massachusetts-based radiopharmaceutical company Lantheus (Nasdaq: LNTH) has announced a plan to acquire clinical-stage ...
The Bakersfield Californian4d
Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive ...
Javascript is required for you to be able to read premium content. Please enable it in your browser settings.
Why Lantheus Holdings Stock Got Thrashed on Tuesday
Well before market open that morning, Lantheus announced that it has signed a definitive agreement to acquire clinical-stage ...